{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wang Y"],"funding":["National Natural Science Foundation of China","National Key Research and Development Program of China"],"pagination":["114701"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9715986"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["283"],"pubmed_abstract":["<h4>Ethnopharmacological relevance</h4>Xuanfei Baidu Decoction (XFBD), one of the \"three medicines and three prescriptions\" for the clinically effective treatment of COVID-19 in China, plays an important role in the treatment of mild and/or common patients with dampness-toxin obstructing lung syndrome.<h4>Aim of the study</h4>The present work aims to elucidate the protective effects and the possible mechanism of XFBD against the acute inflammation and pulmonary fibrosis.<h4>Methods</h4>We use TGF-β1 induced fibroblast activation model and LPS/IL-4 induced macrophage inflammation model as in vitro cell models. The mice model of lung fibrosis was induced by BLM via endotracheal drip, and then XFBD (4.6 g/kg, 9.2 g/kg) were administered orally respectively. The efficacy and molecular mechanis"],"journal":["Journal of ethnopharmacology"],"pubmed_title":["Xuanfei Baidu Decoction protects against macrophages induced inflammation and pulmonary fibrosis via inhibiting IL-6/STAT3 signaling pathway."],"pmcid":["PMC9715986"],"funding_grant_id":["2020YFA0708000","82074032"],"pubmed_authors":["Yang J","Zhu Y","Zhang H","Xue Z","Li L","Chang Y","Sang X","Qin H","Chen X","Gao X","Wang Y","Shao R","Zhang B"],"additional_accession":[]},"is_claimable":false,"name":"Xuanfei Baidu Decoction protects against macrophages induced inflammation and pulmonary fibrosis via inhibiting IL-6/STAT3 signaling pathway.","description":"<h4>Ethnopharmacological relevance</h4>Xuanfei Baidu Decoction (XFBD), one of the \"three medicines and three prescriptions\" for the clinically effective treatment of COVID-19 in China, plays an important role in the treatment of mild and/or common patients with dampness-toxin obstructing lung syndrome.<h4>Aim of the study</h4>The present work aims to elucidate the protective effects and the possible mechanism of XFBD against the acute inflammation and pulmonary fibrosis.<h4>Methods</h4>We use TGF-β1 induced fibroblast activation model and LPS/IL-4 induced macrophage inflammation model as in vitro cell models. The mice model of lung fibrosis was induced by BLM via endotracheal drip, and then XFBD (4.6 g/kg, 9.2 g/kg) were administered orally respectively. The efficacy and molecular mechanis","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-04T19:49:48.247Z","creation":"2025-04-04T19:49:48.247Z"},"accession":"S-EPMC9715986","cross_references":{"pubmed":["34606948"],"doi":["10.1016/j.jep.2021.114701"]}}